An official website of the United States government
Home
Name
Vyxeos
Alternate Names
None
Abbreviations
None
Category
Chemotherapy
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Acute myeloid leukemia
Remarks
August 3, 2017: FDA granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS) for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis.
Coding
This drug should be coded
